COMPASS THERAPEUTICS INC (CMPX) Stock Fundamental Analysis

NASDAQ:CMPX • US20454B1044

6.28 USD
-0.06 (-0.95%)
At close: Feb 13, 2026
6.24 USD
-0.04 (-0.64%)
After Hours: 2/13/2026, 8:00:22 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to CMPX. CMPX was compared to 522 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CMPX as it has an excellent financial health rating, but there are worries on the profitability. CMPX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CMPX had negative earnings in the past year.
  • In the past year CMPX has reported a negative cash flow from operations.
  • In the past 5 years CMPX always reported negative net income.
  • CMPX had a negative operating cash flow in each of the past 5 years.
CMPX Yearly Net Income VS EBIT VS OCF VS FCFCMPX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • CMPX has a better Return On Assets (-21.35%) than 74.57% of its industry peers.
  • With an excellent Return On Equity value of -23.56%, CMPX belongs to the best of the industry, outperforming 80.50% of the companies in the same industry.
Industry RankSector Rank
ROA -21.35%
ROE -23.56%
ROIC N/A
ROA(3y)-27.3%
ROA(5y)-38.44%
ROE(3y)-29.88%
ROE(5y)-44.45%
ROIC(3y)N/A
ROIC(5y)N/A
CMPX Yearly ROA, ROE, ROICCMPX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CMPX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMPX Yearly Profit, Operating, Gross MarginsCMPX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • CMPX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for CMPX has been increased compared to 1 year ago.
  • The number of shares outstanding for CMPX has been increased compared to 5 years ago.
  • CMPX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CMPX Yearly Shares OutstandingCMPX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CMPX Yearly Total Debt VS Total AssetsCMPX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • An Altman-Z score of 28.72 indicates that CMPX is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 28.72, CMPX belongs to the best of the industry, outperforming 92.35% of the companies in the same industry.
  • There is no outstanding debt for CMPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 28.72
ROIC/WACCN/A
WACC12.25%
CMPX Yearly LT Debt VS Equity VS FCFCMPX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

  • A Current Ratio of 17.82 indicates that CMPX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 17.82, CMPX belongs to the top of the industry, outperforming 94.65% of the companies in the same industry.
  • CMPX has a Quick Ratio of 17.82. This indicates that CMPX is financially healthy and has no problem in meeting its short term obligations.
  • CMPX has a better Quick ratio (17.82) than 94.65% of its industry peers.
Industry RankSector Rank
Current Ratio 17.82
Quick Ratio 17.82
CMPX Yearly Current Assets VS Current LiabilitesCMPX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The earnings per share for CMPX have decreased strongly by -21.62% in the last year.
EPS 1Y (TTM)-21.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 28.97% on average over the next years. This is a very strong growth
  • CMPX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 235.05% yearly.
EPS Next Y-19.15%
EPS Next 2Y-10.95%
EPS Next 3Y-10.72%
EPS Next 5Y28.97%
Revenue Next Year-100%
Revenue Next 2Y193.91%
Revenue Next 3Y331.62%
Revenue Next 5Y235.05%

3.3 Evolution

CMPX Yearly Revenue VS EstimatesCMPX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
CMPX Yearly EPS VS EstimatesCMPX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • CMPX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CMPX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMPX Price Earnings VS Forward Price EarningsCMPX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMPX Per share dataCMPX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

  • A cheap valuation may be justified as CMPX's earnings are expected to decrease with -10.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.95%
EPS Next 3Y-10.72%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CMPX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

COMPASS THERAPEUTICS INC

NASDAQ:CMPX (2/13/2026, 8:00:22 PM)

After market: 6.24 -0.04 (-0.64%)

6.28

-0.06 (-0.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05
Earnings (Next)02-27
Inst Owners74.43%
Inst Owner Change-96.56%
Ins Owners6.62%
Ins Owner Change3.65%
Market Cap1.12B
Revenue(TTM)850.00K
Net Income(TTM)-49.38M
Analysts87.62
Price Target13.5 (114.97%)
Short Float %16.16%
Short Ratio10.46
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.34%
Min EPS beat(2)-12.3%
Max EPS beat(2)42.98%
EPS beat(4)1
Avg EPS beat(4)3.69%
Min EPS beat(4)-12.3%
Max EPS beat(4)42.98%
EPS beat(8)3
Avg EPS beat(8)7.29%
EPS beat(12)6
Avg EPS beat(12)11.28%
EPS beat(16)8
Avg EPS beat(16)-0.81%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.5%
PT rev (3m)2.49%
EPS NQ rev (1m)4.07%
EPS NQ rev (3m)15.58%
EPS NY rev (1m)0.92%
EPS NY rev (3m)20.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1314.07
P/FCF N/A
P/OCF N/A
P/B 5.33
P/tB 5.33
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0
BVpS1.18
TBVpS1.18
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.35%
ROE -23.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.3%
ROA(5y)-38.44%
ROE(3y)-29.88%
ROE(5y)-44.45%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.01%
Cap/Sales 2.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 17.82
Quick Ratio 17.82
Altman-Z 28.72
F-Score3
WACC12.25%
ROIC/WACCN/A
Cap/Depr(3y)12.9%
Cap/Depr(5y)74.97%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-19.15%
EPS Next 2Y-10.95%
EPS Next 3Y-10.72%
EPS Next 5Y28.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y193.91%
Revenue Next 3Y331.62%
Revenue Next 5Y235.05%
EBIT growth 1Y-12.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.86%
EBIT Next 3Y-10.13%
EBIT Next 5Y20.19%
FCF growth 1Y-15.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.78%
OCF growth 3YN/A
OCF growth 5YN/A

COMPASS THERAPEUTICS INC / CMPX FAQ

What is the fundamental rating for CMPX stock?

ChartMill assigns a fundamental rating of 3 / 10 to CMPX.


Can you provide the valuation status for COMPASS THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to COMPASS THERAPEUTICS INC (CMPX). This can be considered as Overvalued.


Can you provide the profitability details for COMPASS THERAPEUTICS INC?

COMPASS THERAPEUTICS INC (CMPX) has a profitability rating of 1 / 10.


What is the expected EPS growth for COMPASS THERAPEUTICS INC (CMPX) stock?

The Earnings per Share (EPS) of COMPASS THERAPEUTICS INC (CMPX) is expected to decline by -19.15% in the next year.